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ABSTRACT
Background and the purpose of the study: Olanzapine is an antipsychotic used in treatment of 
schizophrenia. This research was carried out to design oral controlled release matrix pellets 
of water insoluble drug Olanzapine (OZ), using blend of Sodium Alginate (SA) and Glyceryl 
Palmito-Stearate (GPS) as matrix polymers, micro crystalline cellulose (MCC) as spheronizer 
enhancer and Sodium Lauryl Sulphate (SLS) as pore forming agent. 
Methods: OZ formulations were developed by the pelletization technique by drug loaded 
pellets and characterized with regard to the drug content, size distribution, Scanning Electron 
Microscopy (SEM), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared 
Spectroscopy (FTIR) and X-ray Diffraction study (XRD). Stability studies were carried out on 
the optimized formulation for a period of 90 days at 40 ± 2 °C and 75 ± 5% relative humidity. 
Results and major conclusion: The drug content was in the range of 93.34-98.12 %. The mean 
particle size of the drug loaded pellets was in the range 1024 to 1087µm. SEM photographs and 
calculated sphericity factor confirmed that the prepared formulations were spherical in nature. 
The compatibility between drug and polymers in the drug loaded pellets was confirmed by DSC 
and FTIR studies. Stability studies indicated that pellets are stable. XRD patterns revealed the 
crystalline nature of the pure OZ. Loose surface crystal study indicated that crystalline OZ is 
present in all formulations and more clear in formulation F5. Drug release was controlled for 
more than 24 hrs and mechanism of the drug release followed by Fickian diffusion. It may be 
concluded that F5 is an ideal formulation for once a day administration.
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INTRODUCTION
In recent years a wide variety of newer oral drug 
delivery systems like controlled /sustained release 
dosage forms are designed and evaluated to 
overcome the limitations of conventional therapy. 
These  products  are  able  to  maintain  steady  drug 
plasma levels for extended periods of time and as a 
result the variations of the drug levels in the blood are 
prevented and drug related side effects are minimized. 
Olanzapine  (2-methyl-4-(4-methyl-1-piperazinyl)-
10H-thieno[2,3-b][1,5] benzodiazepine) is a potential 
and most commonly used typical antipsychotic, for 
treatment of schizophrenia, acute mania in bipolar 
disorder,  agitation  associated  with  schizophrenia, 
and  bipolar  disorder  (1,  2).  The  starting  dose  of 
OZ is a single evening dose of 10 mg and the usual 
maximum dose is 20 mg. It is practically insoluble 
in  water  and  has  only  60%  oral  bioavailability. 
Based upon individual patient characteristics dosage 
adjustments may be required (3). 
OZ should be given in at least two doses along with an 
additional maintenance dose per day. Due to its low 
therapeutic index, the frequency of adverse effects 
may be dose related. A controlled release dosage form 
is preferable than the conventional one, because there 
is a considerable savings in nurses’ and pharmacists’ 
time. As demonstrated by pharmacokinetic studies 
on OZ, the ingestion of a single controlled release 
formulation  is  effective  even  when  administered 
once a day. Some schizophrenic patients hide a 
conventional tablet under their tongues to avoid 
its daily dose for an atypical antipsychotic. Also 
schizophrenic patients with dysphagia are not able 
to swallow conventional OZ tablet (4). To overcome 
this problem an attempt was made to formulate and 
evaluate controlled release dosage forms of OZ by 
making matrix pellets to improve the solubility of 
OZ which in turn would lead to enhancement of the 
dissolution of OZ.
Evidences  have  shown  in  the  recent  years  that 
hydrophilic and hydrophobic carriers materials 
have the physical properties suitable to prepare 
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gastro-resistant, biocompatible, biodegradable 
matrix pellets to release the entrapped drug in the 
intestinal lumen (5). In the present study, a novel 
extrusion/spheronization  method  was  employed 
using inert hydrophilic and hydrophobic carrier 
materials and non-toxic solvents to load the 
drug into pellets. SA is a natural polymer that is 
very  promising  and  has  been  widely  exploited 
in pharmaceutical industry, because of its tailor 
made  to  suit  the  demands  of  applications  (6). 
SA has the advantages of being non-toxic orally, 
high biocompatibility, and inability to reswell in 
acidic environment, whereas they easily reswell in 
an alkaline environment. So acid sensitive drugs 
incorporated  into  the  beads  would  be  protected 
from  gastric  juice.  The  chief  characteristic  of 
sodium alginate is impermeability to gastric 
juices  and  susceptibility  to  intestinal  juices  (7). 
Dispersion of finely divided poorly water soluble 
drug in hydrophilic and lipidic carriers is an 
interesting technique for the production of matrix 
pellets (8). Different methods have been applied 
for the preparation of lipidic matrix based pellets 
by  extrusion/spheronization  (9).  The  interest  in 
pellets  as  dosage  forms  (filled  into  hard  gelatin 
capsules or compressed into disintegrating tablets) 
has increased continuously.
A thorough literature search revealed a lack of 
information on combination of hydrophilic SA and 
hydrophobic  (GPS)  based  pellets  for  controlled 
drug release, using spheronizer enhancer MCC 
and SLS (0.1% w/v) as a leachable pore forming 
and  wetting  agent.  GPS  act  as  an  inert  matrix 
and drug is released very slowly as compared to 
hydrodispersible, hydrophilic matrix gelucire 50/13 
(10). GPS has been reported as a solidifier which 
controls the drug release, protects the hygroscopic 
substances and facilitates the incorporation of 
liposoluble active ingredients and preservative for 
lipids, oils, waxes and solvents (11). MCC has been 
incorporated in most formulations via extrusion-
spheronisation, because it enhances the rheological 
properties of the wetted mass, resulting in good 
sphericity, low friability, high density and smooth 
surface for successful extrusion-spheronization 
(12). In the present study controlled release pellets 
were  developed  by  extrusion-spheronization  of 
OZ/SA/  GPS  by  addition  of  MCC  with  SLS  to 
tailor drug release. The aim was to develop OZ 
suitable for once daily formulation and examine 
the  influences  of  various  process  parameters  on 
physicochemical properties of the pellets and drug 
release potential. 
MATERIAL AND METHODS
Materials
Olanzapine was a gift sample from Microlabs, India. 
Sodium Alginate  was  a  gift  sample  from  F.M.C. 
International biopolymers, Ireland. GPS, SLS and 
microcrystalline cellulose were procured from Loba 
Chemie, India. Solvents and other chemicals were of 
analytical grade. 
Methods
Preparation of pellets 
The  pellets  were  prepared  by  pelletization 
technique  using  extrusion/spheronization.  OZ, 
SA, GPS and MCC were passed through sieve No. 
40 prior to pelletization and mixed uniformly in a 
planetary mixer. The bubble free SLS (0.1% w/v) 
solution was added dropwise to the mixture and 
mixed for 30 min. The obtained dough mass was 
extruded using a screw extruder (1 mm orifice, 
Kalweka, India). The extrudates were immediately 
spheronized for 6 min at a rotational speed of 400 
rpm and an air velocity of 1 kg/cm2. The pellets 
were  dried  overnight  at  room  temperature  and 
cured at 40 °C for 24 hrs in a tray dryer (Kothari, 
India) (13).
Micromeritic properties (13)
Angle  of  repose  (θ)  was  assessed  to  know  the 
flowability  of  matrix  pellets,  by  a  fixed  funnel 
method. Tap density and bulk density of the pellets 
was  determined  using  tap  density  tester  (TDT, 
Electrolab, India). Granule density of the pellets was 
determined by displacement method using petroleum 
ether. For the friability test, pellets of known mass 
were  placed  in  a  Roche  Friability  tester  (Electro 
lab Friability tester, EF -2, India) and subjected to 
testing at 25 rpm for 4 min. 
Particle size analysis
The particle sizes of drug loaded formulations were 
measured by an optical microscope (Olympus model, 
SZX-12) having resolution of 40X. 
Scanning electron microscopy analysis (SEM)
The shape and surface characteristics were determined 
by scanning electron microscopy (model-LV 5600, 
Jeol, USA). 
Pellet Sphericity
Photomicrographs were taken with a digital camera 
(Sony,  DSC  T-4010.Cyber  shot,  Japan)  and  were 
processed by the image analysis software (Digimizer, 
USA) to characterize each individual pellet by two-
dimensional shape factor (eR) 
eR=2πr/Pm-(b/l)2                                                  (6)
where r is the radius, Pm is the perimeter, l is the 
length and b is the width of the pellet (13). 
Internal pore structure 
To determine the internal pore structure, computed 
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GE-India) was used. 
Differential scanning calorimetry (DSC)
The  DSC  scans  of  the  samples  were  recorded 
using Du Pont thermal analyzer with 2010 DSC 
module  in  nitrogen  atmosphere  at  a  heating  rate  of                   
10 °C/min. 
Fourier transform- infrared spectroscopic analysis 
(FT- IR)
Spectra were obtained by powder diffuse reflectance 
on  a  FTIR  spectrophotometer  (Shimadzu,  Model 
8400S, Japan) in the wave number region of 400-
4000 cm-1 using KBr pellet method.
X-Ray Diffractometery  
X-ray diffraction patterns were recorded using X-
ray diffractometer (Phillips PW 1710, Tokyo, Japan) 
with a copper target, voltage 40 Kv, current 30 MA 
at a scanning speed of 0.30 °C/min. 
  
Determination of drug content  
One hundred milligrams of pellets were dissolved 
in  100  ml  of  methanol.  The  resulting  solution 
was  analyzed  spectrophotometrically  at  274  nm 
(Shimadzu-1601, Japan) after suitable dilution with 
phosphate buffer (pH 7.4) (14). 
Loose Surface Crystal Study (LSC)
One hundred milligrams of pellets was suspended 
in 100 ml of phosphate buffer (pH 7.4). The amount 
of  drug  was  analyzed  spectrophotometrically  at                   
274 nm (14). 
In vitro drug release studies 
USP XXI dissolution apparatus, type II (Electrolab, 
TDT-06L, India) was employed to study the drug 
release. Drug loaded pellets equivalent to 10 mg of 
OZ, were taken in 900 ml of the dissolution medium 
(2 hrs in hydrochloric acid buffer (pH 1.2) and 22 hrs 
in phosphate buffer (pH 7.4)) at 37±0.5 °C and then 
were centrifuged at 100 rpm. The data, thus obtained 
was fit into Peppas model. 
Mt/M∞ = Ktn                                                                                                    (1) 
Mt/M∞ is the fraction of drug released at time t; K 
is the constant comprising structural and geometric 
characteristics of the formulation; and n, the release 
exponent is a parameter that depends on the release 
mechanism. 
M t/M∞=[1-8/π2]exp (-π2Dt/4δ²) for 0.4<Mt/M∞<1   (2)
The diffusivity was calculated to measure diffusion 
of drug molecules from the pellets by using the 
above  equation.  D  is  the  diffusivity  and  δ  is  the 
average radius of pellets. A differential factor (f1) 
and similarity factor (f2) were calculated according 
to the following equations:
f1 =
∑
n
t=1  [Rt - Tt ]
× 100 (3)
∑
n
t=1 Rt
f2 = 50 log {[ 1+(
1) ∑
n
t=1 
(Rt - Tt )2]
-0.5
}
 
×100 (4)
n
  
where, n is number of point, Rt is dissolution value 
and Tt is time value ‘t’. 
Stability studies of pellets
Pellets were filled into a hard gelatin capsules and 
sealed in an aluminum packaging. The studies were 
performed at 40±2 °C and 75±5% relative humidity 
(RH) for 90 days (Thermolab, India). 
RESULTS AND DISCUSSION 
The present method of preparation is quite different 
from that reported by Siepman et al (15)  and 
examines the influence of various process parameters 
on physicochemical properties and drug release 
potential from pellets. 
In the present study, optimized concentration of 20% 
w/w of SA, 5% w/w of GPS, 55% w/w of MCC and 
0.1% w/v of SLS aqueous solution (as pore forming 
agent) was used to produce spherical pellets. It was 
found that when higher or lower concentrations of SA, 
GPS, MCC and SLS were used, the produced pellets 
were  not  spherical  and  not  easy  to  distinguish  as 
individual pellets (16). A spheronization speed of 400 
rpm and residence time of 6 min was used to obtain 
reproducible and uniform sized pellets (Table 1). 
Particle size analysis data (Table 2) indicated that 
the prepared pellets were in the size range of 1024 
to1212  µm  and  56.3-63.6%  and  of  size  fraction 
1212 µm. 
The values of angle of repose (θ0), tapped density, 
granule  density,  %  Carr’s  index  and  Hausner 
ratio (1.023 to 1.165) values indicated good flow 
potential  for  the  prepared  pellets.  The  friability 
of the OZ pellet formulations was found to be in 
the range 0.39-0.53%. Additionally, pellets which 
were cured at 40 °C for 24 hrs had good mechanical 
strength which may be due to sufficient moisture 
content (16).  
SEM photomicrograph Fig. 1, showed that the 
pellets were spherical in nature and had a smooth 
surface when they cured after 24 hrs at 40 °C (17).
From the photomicrograph image analysis, calculated 
Aspect Ratio (AR) and two-dimensional shape factor 
(eR) was found to be 1.03 and 0.89, respectively. The 
obtained AR and eR values of the pellets were closer 
to the value of 1, which confirmed that the prepared 
pellets were spherical in nature (18).
Nano CT-scanning of OZ loaded matrix pellets (F5) 
containing pore structure are presented in figure 2. 
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pellets was found to be 42.5±0.6% and 0.7±0.3 µm, 
respectively. 
Results of the FTIR studies (Fig. 3) showed peaks at 
2932.10 cm-1 due to C-H stretching, at 1586.10 cm-1 
due to C=C stretching, at 1559.21 cm-1 due to C=N 
stretching, at 1225.78 cm-1 due to N-H stretching, 
at 1033.96 cm-1 due to O-H bending and at 745.88 
cm-1 due to C-S bending which are the characteristic 
bands for important functional group of pure drug 
and drug-loaded pellets. FTIR spectra showed that 
after successful encapsulation the characteristics 
bands of OZ were not altered and their positions had 
not changed, indicating no chemical interactions 
between the drug and excipients used. 
XRD pattern of pure OZ showed principal peak at 
20.87° and intense peaks at 8.48°, 18.22°, 19.69°, 
21.39°, 23.84° and OZ loaded matrix pellets ( F5) 
showed  intense  peaks  at  20.95°,  8.58°,  19.85°, 
21.45°,  22.21°,  23.89°  as  presented  in  figure  4. 
The diffractogram of OZ loaded matrix pellets (F5) 
showed broad peaks with low intensity, which may 
be  attributed  to  the  incorporation  of  OZ  between 
parts of the crystal lattice of the SA, leading to a 
change in the degree of crystallinity of the OZ (19). 
OZ  exhibited  a  sharp  endothermic  peak  at                   
196.26  °C  presented  in  figure  5.  There  was  an 
endothermic peak of the drug at 193.19 °C in the 
drug OZ loaded matrix pellets (F5) which indicates 
that the drug is uniformly distributed in the pellets.
Interestingly, drug content and drug encapsulation 
efficiency  as  is  shown  in  table  2,  increased  by 
increase  in  pellets  size  (1024  to1212  µm)  which 
might be due to increase in the relative surface area 
of the pellets (20). 
Parameters           Formulation                                                                               Parameters        Description  of  pellets                                                           
OZ:SA:GPS:MCCa (w/w%)         F1 20 : 40 : 01 : 39 Rod shape and brittle
F2 20 : 35 : 02 : 43 Egg shape  and brittle
F3 20 : 30 : 03 : 47 Semi spherical and brittle
F4 20 : 25 : 04 : 51 Spherical and brittle
F5 20 : 20 : 05 : 55 Spherical and hard
Spheronization speed F5 150 Rod shape
(rpm) 200 Egg shape
300 Semi spherical
400 Spherical
Spheronization speed           F5 3 Rod shape
(time)   4 Egg shape
   5 Semi spherical
6 Spherical
Yield (%)           F1         92.5 Rod shape and brittle
          F2     93.1 Egg shape and brittle
          F3  94.9 Spherical and hard
          F4  95.5 Spherical and brittle
          F5   96.3 Spherical and brittle
aOZ=Olanzapine, SA=Sodium alginate, GPS=Glyceryl palmito-stearate , MCC=Microcrystalline cellulose
Table 1. Optimization of process parameters for pelletization.
No.
Yield  
(%)
Average 
size (µm)
Angle of 
repose θ0
Tapped density   
(g/cm3)
Granule  density  
(g/cm3)
Carr’s 
index (%)
H a u s n e r        
ratio (%)
Friability 
(%)
Drug loading
( mg)
Encapsulation 
efficiency (%)
F1 91.22 1024 27.23 0.821 1.024 8.91 1.023 0.39 16.23 95.13
F2 92.80 1087 26.12 0.854 1.056 8.65 1.165 0.42 16.65 95.89
F3 93.12  1134  25.13 0.828 1.054 8.45 1.145 0.45 17.43 96.32
F4 94.45 1189 26.43 0.873 1.076 8.78 1.098 0.49 17.96 96.78
F5 96.76 1212 26.23 0.896 1.032 9.56 1.123 0.53 18.43 97.42
Table 2. Yield, size distribution, micromeritic properties, friability drug loading and encapsulation efficiency of pellets.Vishal Gupta et al / DARU 2011 19 (4) 249-256 253
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Figure 1. SEM photomicrograph of OZ loaded pellets (F5) in spherical shape  
Figure 1. SEM photomicrograph of OZ loaded pellets (F5) in 
spherical shape.
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              Figure 2. Nano CT – scan showing internal pore structure of a porous pellet (F5) 
Equivalent diameter 367 µm
Maximum inscribed diameter 49 µm
Figure 2. Nano CT-scan showing internal pore structure of a             
porous pellet (F5).
The amount of surface drug determined by loose 
surface crystal study was found to be minimal (1.2-
2.8%) (13).
In vitro release studies indicated that higher amount 
of OZ was released from formulation F5 (96.23%) 
and Olanex– 10 mg tablet (97.12) as compared to 
all other formulations, F1 (85.34%), F2 (86.23%), 
F3 (87.98%) and F4 (88.78%). This result clearly 
indicates  that  lower  drug  was  released  for  the 
systems containing higher content of SA. Because 
SA  particles  are  highly  water  swellable  forms 
leading to higher viscosity, it retards the penetration 
of dissolution media into pellets, thus limiting the 
drug release from pellets (21). 
The rate of drug release followed first order kinetics 
and  numerical  data  fitted  into  Peppas’  equation. 
Statistically estimated values of n of the drug from 
pellets at 95 % confidence limit, was in the range 0.32 
to 0.40 for formulations F1-F5 and 0.40 for Olanex-
10 mg tablet, indicating that the drug was Fickian 
diffusion. The  obtained  correlation coefficient,  R2 
for the OZ loaded pellets was in the range of 0.979-
0.998 and the same result was obtained for Olanex-
10 mg tablet (0.997).  
The drug release profiles of the optimized formulation 
F5  compared  with  oral  formulation  Olanex-10 
mg tablet shown in figure 6 indicates that the drug 
release  from  formulation  F5  pellets  is  controlled 
much better than the commercially available product 
Olanex-10 mg tablet. 
The differential factor (f1) and similarity factor (f2) 
obtained from dissolution profile indicates that the 
formulation  F5  (9.12,  9.56)  and  Olanex-10  mg 
tablet (78.34, 79.13) were similar. 
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            Figure 3. FTIR spectra of OZ (peak A) and OZ loaded matrix pellet (peak B – F5)
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Figure 3. FTIR spectra of OZ (peak A) and OZ loaded matrix pellet (peak B-F5).Olanzapine matrix pellets for controlled release 254
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Figure  4.  X-ray  powder  diffraction  patterns  of  sodium  alginate  (A),  Glyceryl  palmito 
stearate (B), Micro crystalline cellulose (C), Olanzapine (D) and Formulation F5 (E)                     
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Figure 4. X-ray powder diffraction patterns of sodium alginate (A), Glyceryl palmito-stearate  (B), Micro crystalline cellulose (C), Olan-
zapine (D) and Formulation F5 (E)
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Figure 5. DSC thermograms of OZ (peak A), and OZ loaded matrix pellets (peak B – F5)
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Figure 5. DSC thermograms of OZ (peak A), and OZ loaded matrix pellets (peak B – F5)
Diffusivity values of all formulations were in the 
range of 0.39 to 0.83 cm2/s. The diffusivity values 
of formulations F1 (0.39 cm2/s) and F2 (0.43 cm2/s)   
were quite low, due to lower amount of GPS, MCC 
and higher amount of SA, resulting in less diffusivity 
of drug in aqueous media. On the other hand, the 
diffusivity values for formulations F3 (0.54 cm2/s), 
F4 (0.65 cm2/s) and F5 (0.83 cm2/s) were higher due 
to higher ratios of GPS, MCC and lower ratio of SA 
which allowed the drug to diffuse easily. 
There was no significant change in the drug content 
(Table 3) from the pellets during stability studies, 
which indicates that formulation F5 exhibited good 
stability during investigation period.
CONCLUSIONS
The objective of the study was to prepare and evaluate 
OZ loaded pellets by extrusion/spheronization for 
controlled release. The method which was employed Vishal Gupta et al / DARU 2011 19 (4) 249-256 255
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Figure 6. Cummulative % release of olanzapine from matrix pellet (F5) and Olanex
® in the 
intestinal environment against time F5 ( ) and Olanex
®– 10 mg tablet ( )
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Figure 6. Cummulative % release of olanzapine from matrix pellet (F5) and Olanex® in the intestinal environment against time F5                               
(  ) and Olanex®– 10 mg tablet ( ).
is  simple,  rapid,  economical  and  did  not  require 
the use of toxic solvents. Pellets containing a pore 
forming agent, aqueous SLS, formed micropores on 
the surface. The results of micromeritic properties, 
hausner ratio and friability of the pellets were well 
within the limit, which indicated good flow potential 
for the prepared pellets. Drug loaded pellets 
were  spherical  in  nature  as  evidenced  by  SEM 
photomicrographs and sphericity studies. From the 
FTIR and DSC studies, it was observed that there 
was no chemical ineraction between the used drug 
and polymers indicating that drug was in stable form. 
X-ray  diffraction  patterns  revealed  the  crystalline 
nature of pure OZ. The drug content study revealed 
uniform distribution of the drug in the pellets. The 
results of in vitro drug release showed the order of 
formulation F5 > F4 > F3 > F2 > F1. The drug release 
rate varied among the formulations depending on 
the compositions of polymers used. The obtained 
dissolution data indicated that the drug release 
follows fickian diffusion. Optimized formulation F5 
and marketed product Olanex-10 mg tablet showed 
similarity in drug release profile. Formulation F5 is 
an ideal formulation for once daily administration. 
From the present work, it may be concluded that the 
prepared matrix pellets demonstrate the potential 
use of SA/GPS/MCC blend for the developoment 
of controlled drug delivery systems for many water 
insoluble drugs.
Sampling time (days) Drug content a( % )
00 97.42±0.56
15 97.41±0.52
45 97.38±0.68
90 97.37±0.69
a mean±standard deviation, n=3
Table 3.  Results  of  stability  studies  of  pellets  (F5)  stored  at                   
40 °C and 75% RH
REFERENCES
1.  Maxine XP, Anthony SD. Why aren’t depot antipsychotics prescribed more often and what can be done 
about it. Adv. Psych. Treat., 2005; 11: 203-211.
2.  Tollefson GD, Sanger TM. Negative Symptoms: a path analytic approach to a double- blind, placebo- and 
haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry, 1997; 4: 154-164. 
3.  Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin. Neuropharmacol., 2003; 
26: 58-61. 
4.  Kurtz D, Bergstrom R, McDonnell D, Mitchell M. Pharmacokinetics (PK) of multiple doses of olanzapine 
long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized 
patients with schizophrenia. Biol. Psychiatry, 2008; 63: 228-235. 
5.  Masazumi K, Hiroaki N. Development of controlled release matrix pellets by annealing with micronized 
water-insoluble or enteric polymers, J. Contr. Rel., 2002; 82: 335-343.
6.  Ponghanaghakul T, Puttipipatkhachorn S. Alginate-magnesium aluminum silicate film: Effect of plasticizer 
film properties, drug permeation and drug release from coated tablets. Int. J. Pharm., 2007; 333: 34-44. 
7.  Kibbe AH. Hands on book of Pharmaceutical Excipients. 3rd ed. London: Association of Pharmaceutical Olanzapine matrix pellets for controlled release 256
society of Great Britain. 2000.
8.  Chauhan B, Shimpi S, Paradkar A. Preparation and characterization of etoricoxib solid dispersions using 
lipid carriers by spray drying technique. AAPS Pharm. Sci. Tech., 2005; 6: 48–55
9.  Fieldman E, Newton JM. Encyclopedia of pharmaceutical technology, New York, Marcel Dekker. 2002; 
399-417. 
10.  Pongajanyakul T, Natalie JM, Ian TG. Melted glyceryl palmito stearate pellets for protein delivery. Int .J. 
Pharm., 2004; 271: 53-62. 
11.  Kleinebudde P. The crystallite-gel-model for microcrystalline cellulose in wet granulation, extrusion and 
spheronization. Pharm. Res., 1997; 14: 804-809.
12.  Repka  MA,  Sunil  KB,  Sampada  UB,  Sridhar  T,  Michael  CM,  Feng  Z,  Charles  M,  McGnity  JW. 
Pharmaceutical application of hot melt extrusion-part II. Drug. Dev. Ind. Pharm., 2007; 33: 1043-1057. 
13.  Gowda DV, Rajesh N, Afrasim M, Shivakumar HG, Siddaramaiah H. Controlled release behaviour of 
nifedipine from the pellets of gellucire/ microcrystalline cellulose blends. Int. J. Pharm Tech. Res., 2010; 
2: 1215-1226.
14.  Prameela RA, Bala SC. Development of HPLC method for the determination of olanzapine in bulk and 
dosage forms. Int. J. Pharm. Tech. Res., 2009; 1: 654-657. 
15.  Siepmann F, Muschert S, Flament MP, Leterme P, Gayot A, Siepmann A. Controlled drug release from 
gelucire based matrix pellets: experiment and theory. Int. J. Pharm., 2006; 317: 136-143.
16.  Basist AW, Newton JM., Lacey LF. Formulation of ranitidine pellets by extrusion spheronization with 
little or no microcrystalline cellulose. Pharm. Dev. Tech., 1999; 4: 499-505.
17.  Gowda DV, Rajesh N, Shivakumar HG, Siddaramaiah, Nawaz M. Development and evaluation of oral 
controlled release aceclofenac sodium pellets. Pharm. Sci. Monit., 2011; 2: 82-104.
18.  Gowda DV, Ravi V, Shivakumar HG, Siddaramaiah H. Preparation, evaluation and bioavailability studies 
of indomethacin bees wax microspheres. J. Mater. Sci. Mater. Med., 2009; 20: 1447-1456.
19.  Manisha  T,  Garima  C,  Arvind  KB.  Quantification  of  olanzapine  polymorphs  using  powder  X-ray 
diffraction technique. J. Pharm. Biomed. Anal., 2007; 43: 865-872.
20.  Kulkarni AS, Ghadge DM, Kokate PB. Formulation and in vitro evaluation of orally disintegrating tablets 
of olanzapine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Iran. J. Pharma. Res., 2010; 9: 335-
347. 
21.  Rajesh KS, Khanrah A, Biswanath S. Release of ketoprofen from alginate microparticles containing film 
forming polymers. J. Sci. Ind. Res., 2003; 27: 965-989